ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.